RCKT

Company Overview — What Does ROCKET PHARMACEUTICALS, INC. Do?

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey. ROCKET PHARMACEUTICALS, INC. (RCKT) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Gaurav D. Shah and employs approximately 240 people, headquartered in Lexington, New York. With a market capitalization of $393M, RCKT is one of the notable companies in the Healthcare sector.

ROCKET PHARMACEUTICALS, INC. (RCKT) Stock Rating — Reduce (April 2026)

As of April 2026, ROCKET PHARMACEUTICALS, INC. receives a Reduce rating with a composite score of 26.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.RCKT ranks #3,842 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ROCKET PHARMACEUTICALS, INC. ranks #648 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

RCKT Stock Price and 52-Week Range

ROCKET PHARMACEUTICALS, INC. (RCKT) currently trades at $3.49. The stock lost $0.11 (3.1%) in the most recent trading session. The 52-week high for RCKT is $8.80, which means the stock is currently trading -60.3% from its annual peak. The 52-week low is $2.19, putting the stock 59.4% above its annual trough. Recent trading volume was 2.3M shares, reflecting moderate market activity.

Is RCKT Overvalued or Undervalued? — Valuation Analysis

ROCKET PHARMACEUTICALS, INC. (RCKT) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.37x, versus the sector average of 2.75x.

At current multiples, ROCKET PHARMACEUTICALS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ROCKET PHARMACEUTICALS, INC. Profitability — ROE, Margins, and Quality Score

ROCKET PHARMACEUTICALS, INC. (RCKT) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -89.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -74.8% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

RCKT Debt, Balance Sheet, and Financial Health

ROCKET PHARMACEUTICALS, INC. has a debt-to-equity ratio of 19.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 6.38x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $76M.

RCKT has a beta of 1.32, meaning it is more volatile than the broader market — a $10,000 investment in RCKT would be expected to move 31.5% more than the S&P 500 on any given day. The stability factor score for ROCKET PHARMACEUTICALS, INC. is 19/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ROCKET PHARMACEUTICALS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ROCKET PHARMACEUTICALS, INC. reported revenue of $0 and earnings per share (EPS) of $-2.01. Net income for the quarter was $-247M. Operating income came in at $-257M.

In FY 2025, ROCKET PHARMACEUTICALS, INC. reported revenue of $0 and earnings per share (EPS) of $-2.01. Net income for the quarter was $-223M. Operating income came in at $-232M.

In Q3 2025, ROCKET PHARMACEUTICALS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.45. Net income for the quarter was $-50M. Operating income came in at $-52M.

In Q2 2025, ROCKET PHARMACEUTICALS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.62. Net income for the quarter was $-69M. Operating income came in at $-71M.

Over the past 8 quarters, ROCKET PHARMACEUTICALS, INC. has experienced revenue contraction from $0 to $0. Investors analyzing RCKT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

RCKT Dividend Yield and Income Analysis

ROCKET PHARMACEUTICALS, INC. (RCKT) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

RCKT Momentum and Technical Analysis Profile

ROCKET PHARMACEUTICALS, INC. (RCKT) has a momentum factor score of 33/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 51/100 reflects moderate short selling activity.

RCKT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ROCKET PHARMACEUTICALS, INC. (RCKT) ranks #648 out of 838 stocks based on the Blank Capital composite score. This places RCKT in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing RCKT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full RCKT vs S&P 500 (SPY) comparison to assess how ROCKET PHARMACEUTICALS, INC. stacks up against the broader market across all factor dimensions.

RCKT Next Earnings Date

No upcoming earnings date has been announced for ROCKET PHARMACEUTICALS, INC. (RCKT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy RCKT? — Investment Thesis Summary

The quantitative profile for ROCKET PHARMACEUTICALS, INC. suggests caution. The quality score of 22/100 flags below-average profitability. The value score of 13/100 indicates premium valuation. Momentum is weak at 33/100, a headwind for near-term performance. High volatility (stability score 19/100) increases portfolio risk.

In summary, ROCKET PHARMACEUTICALS, INC. (RCKT) earns a Reduce rating with a composite score of 26.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on RCKT stock.

Related Resources for RCKT Investors

Explore more research and tools: RCKT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare RCKT head-to-head with peers: RCKT vs AZN, RCKT vs SLGL, RCKT vs VMD.